Unlike melanoma, anti-CTLA-4 monotherapy has not undergone extensive testing in the context of large phase III studies leaving open questions around its efficacy across diverse etiologies of chronic liver disease and its ability to induce long-lasting anti-tumour control. Here, CTLA4 is linked to neoplasm.